Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Allergan PLC CEO Brent Saunders warned pharmaceutical manufacturers not to let the election of Donald Trump as president of the US to result in a false sense of security across the industry when it comes to the public controversy over high drug prices.
“I worry today that the pharma industry has a very false sense of relief or security because of a Trump administration and Republican-controlled Congress,” Saunders said, speaking during a panel on drug pricing during the Forbes Healthcare Summit in New York City Dec. 1.
Trump won the election on a populist campaign and the drug pricing issue is a populist issue, he reminded industry. Debate over the cost of pharmaceuticals is not likely to abate because many Americans are “rightfully angry,” Saunders said.
“To think President Trump isn’t a populist, that he won’t jump on the next Epipen scandal and tweet more on a pricing scandal than Hillary Clinton tweeted or anybody else…you are fooling yourself,” he said.
What the drug industry does appear to have won is a short reprieve to address drug pricing without government intervention, Saunders added.
“We have a little bit of time to solve it ourselves, but we don’t have a lot of time,” he said. “The next big scandal will revive the debate.”
Find more content for Scrip here.
Scrip: industry news and insights
By Ian Haydock
As part of broader efforts to pursue novel approaches to common neurological disorders, Eisai uses iPSC-derived cells to help identify potential new drug therapies for Parkinson's.
Topics Parkinson's Disease
Scrip: industry news and insights
By Brian Yang
The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, the Chinese government maintains that the situation is “preventable and controllable.”
Topics $name Infectious Diseases Policy & Regulation Coronavirus
Scrip: industry news and insights
Janssen has returned the rights to an obesity/diabetes drug to originator Hanmi, after Phase II studies failed to achieve glycemic control targets and reflecting development difficulties in the sector. This is the fourth time for the Korean firm to face a U-turn of licensed out compounds.
Request a Demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
Support the development and validation of your strategic plans and ensure commercial decisions are based on marketplace realities. Datamonitor Healthcare offers expert coverage of key diseases, treatments, companies, drugs, market access and market trends. Our primary research with physicians, payers, and KOLs (key opinion leaders) informs our treatment standards data and patient-based forecasts.
Trialtrove is the go-to resource for clinical trial research. Easily track your competitors' clinical R&D activity with expert insights and continually monitored trials.
Biomedtracker provides real-time analysis of major market-moving events in the pharma and biotech industries. With catalyst tracking and expert insights, Biomedtracker helps you stay on top of breaking events, the drugs pipeline, upcoming milestones, companies, and deals – and their impact on the markets you care about.
Looking for more products Product Finder
